Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia

Journal of Clinical Oncology

Volumn 32, Issue 15, 2014, Pages 1586-1594

  Pastore, Friederike ^a,b   Dufour, Annika ^a   Benthaus, Tobias ^a   Metzeler, Klaus H ^a,b   Maharry, Kati S ^j,k   Schneider, Stephanie ^a   Ksienzyk, Bianka ^a   Mellert, Gudrun ^a   Zellmeier, Evelyn ^a   Kakadia, Purvi M ^a,d   Unterhalt, Michael ^a   Feuring Buske, Michaela ^e   Buske, Christian ^e   Braess, Jan ^f   Sauerland, Maria Cristina ^g   Heinecke, Achim ^g   Krug, Utz ^h   Berdel, Wolfgang E ^h   Buechner, Thomas ^h   Woermann, Bernhard ⁱ   Hiddemann, Wolfgang ^a,b   Bohlander, Stefan K ^a,b,d,l   Marcucci, Guido ^j   Spiekermann, Karsten ^a,b   Bloomfield, Clara D ^j   Hoster, Eva ^a,c   more..

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY HOSPITAL MARBURG   (Germany)

^e UNIVERSITY HOSPITAL ULM   (Germany)

^f Barmherzige Brüder Hospital   (Germany)

^g UNIVERSITY OF MÜNSTER   (Germany)

^h UNIVERSITY HOSPITAL MÜNSTER   (Germany)

ⁱ German Society of Hematology and Oncology   (Germany)

^j OHIO STATE UNIVERSITY   (United States)

^k MAYO CLINIC   (United States)

^l UNIVERSITY OF AUCKLAND   (New Zealand)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FLT3 LIGAND; NUCLEOPHOSMIN; CCAAT ENHANCER BINDING PROTEIN; CD135 ANTIGEN; CEBPA PROTEIN, HUMAN; FLT3 PROTEIN, HUMAN; NUCLEAR PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CYTOGENETICS; FEMALE; GENE MUTATION; HUMAN; LEUKEMIA RELAPSE; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RISK MANAGEMENT; AGE; CHROMOSOME ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION SUPPORT SYSTEM; DISEASE FREE SURVIVAL; GENETIC PREDISPOSITION; GENETICS; GERMANY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR; TIME; TREATMENT OUTCOME; VALIDATION STUDY; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CCAAT-ENHANCER-BINDING PROTEINS; CYTOGENETIC ANALYSIS; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENETIC PREDISPOSITION TO DISEASE; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84903821162     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.3480     Document Type: Article

References (40)

1. Byrd JC, Mrózek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002 (Pubitemid 35429670)
2. Grimwade D, Walker H, Harrison G, et al: The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): Analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98:1312-1320, 2001
3. Dufour A, Schneider F, Metzeler KH, et al: Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 28:570-577, 2010
4. Schlenk RF, Döhner K, Krauter J, et al: Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909-1918, 2008 (Pubitemid 351620111)
5. Pabst T, Eyholzer M, Fos J, et al: Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer 100:1343-1346, 2009
6. Wouters BJ, Löwenberg B, Erpelinck-Verschueren CA, et al: Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 113:3088-3091, 2009
7. Kottaridis PD, Gale RE, Frew ME, et al: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752-1759, 2001
8. Fröhling S, Schlenk RF, Breitruck J, et al: Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 100:4372-4380, 2002 (Pubitemid 35434129)
9. Yanada M, Matsuo K, Suzuki T, et al: Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: A meta-analysis. Leukemia 19: 1345-1349, 2005 (Pubitemid 41136326)
10. Kayser S, Schlenk RF, Londono MC, et al: Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome. Blood 114:2386-2392, 2009
11. Döhner H, Estey EH, Amadori S, et al: Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 115:453-474, 2010
12. Büchner T, Berdel WE, Haferlach C, et al: Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: A study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 27:61-69, 2009
13. Schoch C, Kern W, Schnittger S, et al: The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica 89:1082-1090, 2004 (Pubitemid 39295479)
14. Hasford J, Pfirrmann M, Hehlmann R, et al: A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa: Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Natl Cancer Inst 90:850-858, 1998 (Pubitemid 28280552)
15. Hoster E, Dreyling M, Klapper W, et al: A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111:558-565, 2008
16. Büchner T, Berdel WE, Schoch C, et al: Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia. J Clin Oncol 24:2480-2489, 2006 (Pubitemid 46655599)
17. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982 (Pubitemid 13149996)
18. Shaffer LG, Slovak ML, Campbell LJ: An International System for Human Cytogenetic Nomenclature: Recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. Berlin, Germany, Karger Publishers, 2009
19. Falini B, Mecucci C, Tiacci E, et al: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254-266, 2005 (Pubitemid 40110814)
20. Thiede C, Steudel C, Mohr B, et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335, 2002 (Pubitemid 34627197)
21. Benthaus T, Schneider F, Mellert G, et al: Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia. Br J Haematol 143:230-239, 2008
22. Schnittger S, Schoch C, Kern W, et al: Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106:3733-3739, 2005 (Pubitemid 41739006)
23. Altman DG, Lausen B, Sauerbrei W, et al: Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 86:829-835, 1994 (Pubitemid 2100935)
24. Efron B: An Introduction to the Bootstrap. Boca Raton, FL, Chapman & Hall/CRC, 1994
25. Mayer RJ, Davis RB, Schiffer CA, et al: Intensive postremission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med 331:896-903, 1994 (Pubitemid 24299870)
26. Stone RM, Berg DT, George SL, et al: Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia: Cancer and Leukemia Group B. N Engl J Med 332:1671-1677, 1995
27. Baer MR, George SL, Caligiuri MA, et al: Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B Study 9720. J Clin Oncol 26:4934-4939, 2008
28. Baer MR, George SL, Sanford BL, et al: Escalation of daunorubicin and addition of etoposide in the ADE regimen in acute myeloid leukemia patients aged 60 years and older: Cancer and Leukemia Group B Study 9720. Leukemia 25:800-807, 2011
29. Kolitz JE, George SL, Dodge RK, et al: Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: Final induction results of Cancer and Leukemia Group B Study 9621. J Clin Oncol 22:4290-4301, 2004 (Pubitemid 41185150)
30. Lee EJ, George SL, Caligiuri M, et al: Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: Results of Cancer and Leukemia Group B study 9420. J Clin Oncol 17:2831-2839, 1999 (Pubitemid 29415241)
31. Kolitz JE, George SL, Marcucci G, et al: P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood 116:1413-1421, 2010
32. Marcucci G, Moser B, Blum W, et al: A phase III randomized trial of intensive induction and consolidation chemotherapy ± oblimersen, a pro-apoptotic Bcl-2 antisense oligonucleotide in untreated acute myeloid leukemia patients > 60 years old. J Clin Oncol 25, 2007 (suppl 18s; abstr 7012)
33. Damm F, Heuser M, Morgan M, et al: Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 117:4561-4568, 2011
34. Krug U, Röllig C, Koschmieder A, et al: Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: A web-based application for prediction of outcomes. Lancet 376:2000-2008, 2010
35. Pfirrmann M, Ehninger G, Thiede C, et al: Prediction of post-remission survival in acute myeloid leukaemia: A post-hoc analysis of the AML96 trial. Lancet Oncol 13:207-214, 2012
36. Rockova V, Abbas S, Wouters BJ, et al: Risk stratification of intermediate-risk acute myeloid leukemia: Integrative analysis of a multitude of gene mutation and gene expression markers. Blood 118: 1069-1076, 2011
37. Röllig C, Thiede C, Gramatzki M, et al: A novel prognostic model in elderly patients with acute myeloid leukemia: Results of 909 patients entered into the prospective AML96 trial. Blood 116:971-978, 2010
38. Wahlin A, Markevärn B, Golovleva I, et al: Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol 115:25-33, 2001 (Pubitemid 32995089)
39. Wheatley K, Brookes CL, Howman AJ, et al: Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 145:598-605, 2009
40. Swerdlow SH, International Agency for Research on Cancer, World Health Organization: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France, International Agency for Research on Cancer, 2008